Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

Open access

Abstract

OBJECTIVES: We compared the ability of molecular biomarkers for Alzheimer disease (AD), including amyloid imaging and CSF biomarkers (Aβ42, tau, ptau181, tau/Aβ42, ptau181/Aβ42), to predict time to incident cognitive impairment among cognitively normal adults aged 45 to 88 years and followed for up to 7.5 years. METHODS: Longitudinal data from Knight Alzheimer's Disease Research Center participants (N = 201) followed for a mean of 3.70 years (SD = 1.46 years) were used. Participants with amyloid imaging and CSF collection within 1 year of a clinical assessment indicating normal cognition were eligible. Cox proportional hazards models tested whether the individual biomarkers were related to time to incident cognitive impairment. "Expanded" models were developed using the biomarkers and participant demographic variables. The predictive values of the models were compared. RESULTS: Abnormal levels of all biomarkers were associated with faster time to cognitive impairment, and some participants with abnormal biomarker levels remained cognitively normal for up to 6.6 years. No differences in predictive value were found between the individual biomarkers (p > 0.074), nor did we find differences between the expanded biomarker models (p > 0.312). Each expanded model better predicted incident cognitive impairment than the model containing the biomarker alone (p < 0.005). CONCLUSIONS: Our results indicate that all AD biomarkers studied here predicted incident cognitive impairment, and support the hypothesis that biomarkers signal underlying AD pathology at least several years before the appearance of dementia symptoms.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182918ca6

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 226

Metadata

Authors
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., & Morris, J. C.
Affiliations
  • Hope Center for Neurological Disorders (US)
  • From the Knight Alzheimer's Disease Research Center (C.M.R., A.M.F., E.A.G., J.H., K.L.M., D.M.D., T.L.S.B., D.M.H., J.C.M.), Hope Center for Neurological Disorders (A.M.F., D.M.H.), and Departments of Neurology (C.M.R., A.M.F., K.L.M., C.L.S., D.M.H., J.C.M.), Psychology (J.H., D.M.D.), Radiology (T.L.S.B., M.A.M.), Pathology and Immunology (J.C.M.), Physical Therapy (J.C.M.), Occupational Therapy (J.C.M.), and Neurosurgery (T.L.S.B.), and the Division of Biostatistics (E.A.G.), Washington...
Venue
Neurology
Published
2013-05-07
Volume
80
Issue
19
Pages
1784-1791
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2098485296
Cited by
222
References
41
Citations by year
2026: 6 · 2025: 3 · 2024: 9 · 2023: 10 · 2022: 13 · 2021: 17 · 2020: 25 · 2019: 20 · 2018: 22 · 2017: 17 · 2016: 21 · 2015: 25 · 2014: 30 · 2013: 4
FWCI
18.96
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Longer Life Foundation
  • National Institutes of Health (UL1TR000448)
  • Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis
  • National Institute on Aging (P50AG005681, P01AG003991, P01AG026276)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23DK094982)
  • National Institute of Neurological Disorders and Stroke (P30NS057105, NS057105)
  • National Center for Research Resources (UL1RR024992)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, amyloid imaging, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau 181, cognitive impairment prediction, incident cognitive impairment, cognitively normal adults, preclinical Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Dementia, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Time Factors, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182918ca6
The paper
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., & Morris, J. C. (2013). Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. https://doi.org/10.1212/wnl.0b013e3182918ca6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.